Javelin Pharmaceuticals (JAV -14.5%) falls as Hospira (HSP +0.7%) extends its tender offer of $2.20/share for a second time due to concerns about the state of Javelin's business. Javelin files suit to compel Hospira to follow through on the merger agreement.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs